Abstract
As an important part of the immune system, T lymphocytes exhibit undoubtedly an important role in targeting and eradicating cancer. However, despite these characteristics, their natural antitumor response may be insufficient. Numerous clinical trials in terminally ill cancer patients testing the design of novel and efficient immunotherapeutic approaches based on the adoptive transfer of autologous tumor-specific T lymphocytes have shown encouraging results. Moreover, this also led to the approval of engineered T-cell therapies in patients. Herein, we will expand on the development and the use of such strategies using tumor-infiltrating lymphocytes or genetically engineered T-cells. We will also comment on the requirements and potential hurdles encountered when elaborating and implementing such treatments as well as the exciting prospects for this kind of emerging personalized medicine therapy.
Original language | English |
---|---|
Title of host publication | Experientia supplementum (2012) |
Publisher | Springer Basel |
Pages | 253-294 |
Number of pages | 42 |
DOIs | |
State | Published - 2022 |
Publication series
Name | Experientia supplementum (2012) |
---|---|
Volume | 113 |
ISSN (Print) | 1664-431X |
ISSN (Electronic) | 2504-3692 |
Bibliographical note
Publisher Copyright:© 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.
Keywords
- Adoptive Cell Therapy
- CAR-T-cells
- Cancer
- T-cell Receptor
- T-cells engineering
- Tumor-Infiltrating Lymphocytes